Analyst Research

Report Title Price
Provider: Stock Traders Daily
$20.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: GlobalData
$125.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

GlaxoSmithKline Plc receives positive CHMP opinion for Incruse for the treatment of COPD


Friday, 21 Feb 2014 02:00am EST 

GlaxoSmithKline Plc:European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending marketing authorisation for umeclidinium under the proposed brand name Incruse.Says Incruse as a once-daily, maintenance treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease.Says umeclidinium is an investigational long-acting muscarinic antagonist (LAMA).Says the proposed strength is 55mcg inhalation powder contained in the Ellipta.